Medipharm Labs Corp (LABS) - Net Assets

Latest as of March 2026: CA$35.10 Million CAD ≈ $25.39 Million USD

Based on the latest financial reports, Medipharm Labs Corp (LABS) has net assets worth CA$35.10 Million CAD (≈ $25.39 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$43.62 Million ≈ $31.55 Million USD) and total liabilities (CA$8.52 Million ≈ $6.16 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check LABS tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CA$35.10 Million
% of Total Assets	80.46%
Annual Growth Rate	76.51%
5-Year Change	-56.93%
10-Year Change	N/A
Growth Volatility	393.02

Medipharm Labs Corp - Net Assets Trend (2016–2025)

This chart illustrates how Medipharm Labs Corp's net assets have evolved over time, based on quarterly financial data. See Medipharm Labs Corp (LABS) liquidity interval to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Medipharm Labs Corp (2016–2025)

The table below shows the annual net assets of Medipharm Labs Corp from 2016 to 2025. For live valuation and market cap data, see LABS market cap.

Year	Net Assets	Change
2025-12-31	CA$35.81 Million ≈ $25.91 Million	-17.07%
2024-12-31	CA$43.18 Million ≈ $31.24 Million	-18.53%
2023-12-31	CA$53.01 Million ≈ $38.34 Million	-5.36%
2022-12-31	CA$56.01 Million ≈ $40.51 Million	-32.64%
2021-12-31	CA$83.15 Million ≈ $60.15 Million	+6.03%
2020-12-31	CA$78.41 Million ≈ $56.72 Million	-40.25%
2019-12-31	CA$131.23 Million ≈ $94.93 Million	+371.31%
2018-12-31	CA$27.84 Million ≈ $20.14 Million	+1410.88%
2017-12-31	CA$-2.12 Million ≈ $-1.54 Million	-1085.80%
2016-12-31	CA$215.46K ≈ $155.86K	--

Equity Component Analysis

This analysis shows how different components contribute to Medipharm Labs Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 16920028500.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	CA$201.90 Million	563.79%
Other Comprehensive Income	CA$3.29 Million	9.18%
Total Equity	CA$35.81 Million	100.00%

Medipharm Labs Corp Competitors by Market Cap

The table below lists competitors of Medipharm Labs Corp ranked by their market capitalization.

Company	Market Cap
Brooks Laboratories Limited NSE:BROOKS	$21.52 Million
Eastparc Hotel Tbk PT JK:EAST	$21.52 Million
ALUMEXX N.V. NAM. EO-10 F:NE8F	$21.53 Million
Acco Group Holdings Limited Ordinary Shares NASDAQ:ACCL	$21.55 Million
Wonil Special Steel Co. Ltd KQ:012620	$21.50 Million
Higher Way Electronic Co Ltd TWO:3268	$21.50 Million
Siab Holdings Bhd KLSE:0241	$21.49 Million
Shradha Infraprojects Limited NSE:SHRADHA	$21.47 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Medipharm Labs Corp's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 43,184,000 to 35,812,000, a change of -7,372,000 (-17.1%).
Net loss of 8,267,000 reduced equity.
Other comprehensive income decreased equity by 26,113,000.
Other factors increased equity by 27,008,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CA$-8.27 Million	-23.08%
Other Comprehensive Income	CA$-26.11 Million	-72.92%
Other Changes	CA$27.01 Million	+75.42%
Total Change	CA$-	-17.07%

Book Value vs Market Value Analysis

This analysis compares Medipharm Labs Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.82x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has increased from 0.65x to 0.82x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	CA$0.11	CA$0.07	x
2017-12-31	CA$0.08	CA$0.07	x
2018-12-31	CA$0.38	CA$0.07	x
2019-12-31	CA$0.98	CA$0.07	x
2020-12-31	CA$0.57	CA$0.07	x
2021-12-31	CA$0.33	CA$0.07	x
2022-12-31	CA$0.20	CA$0.07	x
2023-12-31	CA$0.15	CA$0.07	x
2024-12-31	CA$0.11	CA$0.07	x
2025-12-31	CA$0.09	CA$0.07	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Medipharm Labs Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -23.08%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -18.32%
• Asset Turnover: 0.99x
• Equity Multiplier: 1.28x
Recent ROE (-23.08%) is above the historical average (-61.68%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	-62.16%	0.00%	0.00x	1.22x	CA$-155.48K
2017	-247.50%	0.00%	0.00x	1.00x	CA$-1.03 Million
2018	-30.42%	-82.48%	0.24x	1.55x	CA$-11.18 Million
2019	0.86%	0.88%	0.77x	1.28x	CA$-12.02 Million
2020	-85.58%	-186.35%	0.30x	1.51x	CA$-74.95 Million
2021	-65.91%	-252.41%	0.24x	1.11x	CA$-63.12 Million
2022	-53.54%	-135.57%	0.34x	1.17x	CA$-35.58 Million
2023	-24.68%	-39.57%	0.52x	1.21x	CA$-18.38 Million
2024	-24.76%	-25.49%	0.78x	1.24x	CA$-15.01 Million
2025	-23.08%	-18.32%	0.99x	1.28x	CA$-11.85 Million

Industry Comparison

This section compares Medipharm Labs Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $498,584,714
Average return on equity (ROE) among peers: -44.91%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Medipharm Labs Corp (LABS)	CA$35.10 Million	-62.16%	0.24x	$21.51 Million
Aurora Cannabis Inc (ACB)	$218.93 Million	-5.92%	0.47x	$170.24 Million
Amotiv Limited (AOV)	$746.87 Million	-2.25%	0.27x	$576.83 Million
Aequus Pharmaceuticals Inc (AQS)	$-6.45 Million	0.00%	0.00x	$479.73K
Avicanna Inc (AVCN)	$6.91 Million	-242.83%	2.23x	$12.74 Million
Avant Brands Inc (AVNT)	$49.33 Million	-10.28%	0.67x	$6.44 Million
Bausch Health Companies Inc (BHC)	$3.26 Billion	-73.94%	12.36x	$1.89 Billion
CanadaBis Capital Inc (CANB)	$7.92 Million	-10.54%	2.10x	$1.53 Million
Cannabist Company Holdings Inc (CBST)	$550.08 Million	-25.79%	1.50x	$12.41 Million
Cipher Pharmaceuticals Inc (CPH)	$126.01 Million	22.07%	0.24x	$297.56 Million
Cardiol Therapeutics Inc Class A (CRDL)	$28.25 Million	-99.58%	0.30x	$118.76 Million

About Medipharm Labs Corp

TO:LABS Canada Drug Manufacturers - Specialty & Generic

Market Cap

$21.51 Million

CA$29.74 Million CAD

Market Cap Rank

#24898 Global

#967 in Canada

Share Price

CA$0.07

Change (1 day)

-6.67%

52-Week Range

CA$0.06 - CA$0.09

All Time High

CA$7.17